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Abstract: Growth retardation, delayed puberty, decreased bone mass, altered bone architecture, hypovitaminosis D and skeletal muscle mass deficits
are common in children with inflammatory bowel diseases. The Crohn’s and Colitis Foundation of America sponsored a multidisciplinary workshop on
the subject of Bone and Skeletal Growth in Pediatric IBD, held in New York City in November 2011. The topic of the workshop was a key
recommendation of the Foundation’s Pediatric Challenges meeting in 2005. The Litwin Foundation provided a generous grant to support this crucial
research and workshop through the CCFA. The workshop featured 15 presentations by researchers from the United States, Canada, Switzerland,
Germany, and the United Kingdom and a number of posters elucidating diverse aspects of the problem of growth retardation and compromised bone
health in pediatric Crohn’s disease and ulcerative colitis. The workshop comprised original, basic, and clinical research and relevant reviews of
underlying genetics, molecular biology, endocrinology, immunology, and bone physiology research. Investigators funded by CCFA and the Litwin
Family Foundation are marked by an asterisk after their name in the text. Workshop presentations fell under 3 broad categories: “Mechanisms of
Suppression and Growth of Bone Cell Function by Inflammation,” “Impact of IBD on Growth and Bone Health,” and “Approaches to Address Growth
Failure and Low Bone Mass in Children with IBD,” summarized herein. We have cited the publications that resulted from this granting mechanism in the
appropriate section and references for pertinent updates on each topic.
(Inflamm Bowel Dis 2013;19:2919–2926)
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MECHANISMS OF SUPPRESSION AND GROWTH
OF BONE CELL FUNCTION BY INFLAMMATION
Inflammation, most notably in children with Crohn’s dis-
ease (CD), can result in growth failure (defined as a growth veloc-
ity less than 22 SD compared with unaffected children) and
altered bone remodeling and modeling. In children with new onset
CD, the activity of bone cells, osteoblasts, and osteoclasts is
decreased probably due to disease and treatment factors.1,2 This
accounts for thinner and potentially weaker bones in pediatric
CD.1,3 One year after diagnosis, 40% of children may exhibit
decreased linear growth velocity and 33% may have persistent
reduction in linear growth 2 years after diagnosis.4 Affected chil-
dren and adolescents can exhibit a lower final height and sub-
optimal peak bone mass.5 The mechanisms underlying these
clinical problems are however not fully understood. Recent prog-
ress on the subject is the focus of the following oral presentations.
MECHANISMS OF INFLAMMATORY BOWEL
DISEASE SUPPRESSION OF SKELETAL GROWTH
AND MINERAL DENSITY
Laura R. McCabe, PhD*
Dr. McCabe and colleagues treated mice with 1% to 5%
dextran sulfate sodium (DSS) in drinking water to induce colitis
and described changes in linear growth, bone mass and architecture,
and bone cell function. In mice that received 5% DSS, growth was
stunted, serum biomarkers of osteoclast and osteoblast activity were
significantly decreased, chondrocyte mass was reduced, and bone
mass was lower. All abnormalities corrected after DSS was
removed and the colon healed suggesting that treating inflammation
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can restore normal growth and bone formation. Remarkably, a subset
of mice treated with 1% DSS did not lose weight yet had active
colitis, a reduction in bone mass, decreased bone formation, and
suppressed mineral acquisition rate. Serum osteoclast and osteoblast
activity markers were consistently low. This suggests that colitis
even without significant weight loss is sufficient to reduce bone mass
acquisition. Serum tumor necrosis factor alpha (TNF-a) was higher
during colitis and may be responsible, at least in part, for the sup-
pression of bone growth and modeling. However, cytokines may be
also produced in the bone microenvironment in response to colonic
inflammation, and activated bone marrow cells may directly suppress
bone formation. Interestingly, male mice had more severe colitis than
females and also showed bone loss where females did not.6
Future Directions
The gut appears to be an important regulator of bone cell
function. Dr. McCabe will continue studying sex differences in
the severity of colitis and in the response to treatments that aimed
at increasing bone mass, such as selected probiotics.7
IMMUNOGENETIC DETERMINANTS OF LINEAR
GROWTH IN PEDIATRIC INFLAMMATORY
BOWEL DISEASE
Lee A. Denson, MD*
Currently, there are no adequate clinical prediction tools for
high risk of growth failure in children with Inflammatory bowel
disease (IBD). Dr. Denson’s research seeks to fill this gap and
identify the risk factors for growth faltering in 2 cohorts of children
with IBD. He is testing 3 hypotheses: (1) linear growth is affected
by disease activity and anti–TNF-a therapy; (2) a subset of patients
will have growth retardation even in the presence of mild or inac-
tive disease; (3) genetic mutations of nucleotide-binding oligomer-
ization domain 2 and autoantibodies to granulocyte macrophage
colony-stimulating factor (GM-CSF) cause intestinal barrier dys-
function and suppression of tissue growth hormone receptors.
Dr. Denson has observed high rates of growth failure at IBD diag-
nosis that persisted 2 years after diagnosis. A modest increase in
growth accompanied anti–TNF-a therapy, however below what
researchers anticipated. This subset of patients did not achieve their
predicted height 2 years after diagnosis. Significantly, the highest
degree of growth failure was associated with the presence of
GM-CSF autoantibodies and nucleotide-binding oligomerization
domain 2 mutations and altered intestinal barrier function8 and
resistance to growth hormone.9 Therefore, therapies directed at
improving barrier function may improve the potential for catch
up growth in children with IBD. A subset of children with CD
and GM-CSF autoantibodies may benefit from GM-CSF therapy.10
Future Directions
To build a model to predict the risk of significant growth
failure and validate findings in a replication cohort of three
hundred patients from the CCFA RISK Study.
GENETICS OF GROWTH FAILURE IN CD
Jonah Essers, MD, MPH
Dr. Jonah Essers submitted that final height of children
with IBD is the result of a combination of genetic, disease,
and treatment factors. As an example, he discussed Dr. Jessica
Lee’s study that examined height z scores of 210 children with
IBD and their parents. The data showed that parents of non–growth-
impaired children with IBD fit the mean z score for adult height,
whereas parents of children with growth impairment are also
shorter. The height z score of unaffected siblings of children
with growth deficits is also shorter than normal. Of the 108
patients with IBD followed into adulthood, mean height z scores
are lower than predicted. Taking into account immunomodula-
tors and biologics, the most important predictors of growth def-
icits are minimum height z score of the patient and height z score
of the parents.11
Future Directions
Future directions will address whether genetic factors (1)
directly influence the biology of growth in pediatric IBD or (2)
worsen the disease behavior, which as a downstream conse-
quence negatively affects growth. Future efforts will need to
refine phenotyping of growth to reflect true growth velocity and
will likely involve querying the whole genome rather than
candidate genes. However, it is unlikely that genetics alone will
be used to predict growth failure except in rare patients with
a strong Mendelian hit. The CCFA RISK Project will provide
a database for evaluation of genetic influences in groups of
clinical IBD phenotypes.
VITAMIN D
Vitamin D increases intestinal calcium absorption, sup-
presses parathyroid hormone (PTH), and promotes normal
bone mineralization, but vitamin D may also have functions
in immune responses, glucose homeostasis, cardiovascular
disease, and cancer prevention.12 Vitamin D seems to be
a potent modulator of both innate and adaptive immunity.12
The vitamin D receptor is present in a wide variety of immune
cells,13–18 and vitamin D receptor polymorphisms confer
increased risk for CD.19
Vitamin D deficiency can stem from low intake,
decreased skin production, impaired absorption, obesity,
renal, and hepatic failure or loss of 25-hydroxy-vitamin D
(25OHD). Winter, aging, skin pigmentation, and use of sun
block affect cutaneous synthesis. Certain medications like
anticonvulsants, antiretrovirals, corticosteroids, and cyclo-
sporine are associated with vitamin D deficiency. The Institute
of Medicine and the Endocrine Society recommend 25OHD
testing for those at risk for vitamin D deficiency.20,21 Because
vitamin D deficiency is common in children and adolescents
with IBD, a serum 25OHD level should be obtained at least
yearly.22
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RELEVANCE OF VITAMIN D TO THE
INTESTINAL MICROBIOME
Martin Hewison, PhD
There are numerous lines of evidence that implicate
a potential role for vitamin D deficiency in IBD onset and disease
severity. Vitamin D may enhance intestinal innate immunity, thus
helping to control the density and diversity of the gut flora.
Vitamin D may also prevent chronic intestinal inflammation from
taking place by suppressing the activation of the adaptive immune
system in the gut.23 Unlike the renal 1-a hydroxylation of
vitamin D by CYP27B1, which is regulated primarily by PTH,
the tissue concentration of 1,25-dihydroxy vitamin D (1,25
(OH)2D) is mainly regulated by the availability of 25OHD. This
is relevant to IBD because 1,25(OH)2D, is a potent stimulator of
nucleotide-binding oligomerization domain 2, an important intra-
cellular microbial recognition receptor24 and the production of
cathelicidin in macrophages.15 Therefore, vitamin D deficiency
may result in dysbiosis and contribute to the inflammatory
response in IBD. In addition, experimental manipulations that
reduce the intestinal concentration of 1,25(OH)2D increase the
severity of DSS-induced colitis in mice and produce aberrant
innate immune responses (e.g., reduced antimicrobial peptides)
to enteric bacteria.25,26 These observations show that vitamin D
can have an impact on the gut microbiota in several ways:
enhanced bacterial killing, improved surveillance of enteric bac-
teria, altered composition of microbiota, and modulation of adap-
tive immune components. Dr. Hewison’s observations suggest
that vitamin D deficiency may be an environmental factor that
plays a role in IBD pathogenesis.
In a subset of patients with CD, there may be an over
production of 1,25(OH)2D, similar to what happens in other gran-
ulomatous diseases.27 The precise mechanism causing overactiva-
tion of vitamin D and hypercalcemia in CD is unclear but may
involve effects of enteric bacteria acting to enhance the vitamin D
system within patient gastrointestinal tissues.
Future Directions
To determine if vitamin D supplementation in patients with
IBD affects gut immune responses and disease severity.
VITAMIN D IN PEDIATRIC
AUTOIMMUNE DISEASES
Jon M. Burnham, MD, MSCE
Systemic lupus erythematosus (SLE), like IBD, is a chronic
inflammatory disease that can affect children and adults. Like in
IBD, there is evidence that vitamin D may help patients with SLE.
Low serum vitamin D is associated with increased disease activity
is pediatric28 and adult SLE,29 suggesting that supplementation of
vitamin D may help reduce SLE disease activity. For example,
a pilot study in pediatric SLE showed that 15,000 to 30,000 IU
vitamin D per week improved 25OHD serum levels without
a change evident in serum calcium or urine calcium/creatinine
ratio.30 However, it has not yet been tested if correcting vitamin
D deficiency in SLE improves disease outcomes.
Interferon alpha (IFN-a)–induced gene expression is a bio-
marker for measuring disease activity in SLE.31 Dr. Burnham
chairs a clinical trial funded by the Autoimmunity Centers of
Excellence and sponsored by the National Institute of Allergy
and Infectious Diseases to determine whether high-dose
vitamin D3, compared with standard dose, improves the IFN-a
signature in children with SLE and vitamin D deficiency over
a 3-month period (NCT01709474). In addition, changes in glu-
cose homeostasis and biomarkers of bone metabolism will be
measured.
Future Directions
In pediatric autoimmune/inflammatory conditions, studies
are needed to determine whether vitamin D influences suscepti-
bility, severity, persistence, and tissue damage and whether
vitamin D supplementation can optimize clinical outcomes.
BONE CELL METABOLISM AND INFLAMMATION
Bone tissue is remodeled continuously throughout life by
discrete multicellular units, where bone matrix is produced by
osteoblasts and resorbed by osteoclasts in a coordinated effort to
maintain bone mass, bone architecture, and bone strength. In
addition, during growth and development, both osteoblasts and
osteoclasts are active in a process called bone modeling. Both
bone remodeling and modeling are susceptible to chronic
intestinal inflammation. The following section discusses research
opportunities in osteoimmunology.32
INFLAMMATORY TARGETS IN KEY
DEVELOPMENTAL SIGNALS OF OSTEOBLASTS
Stefano Zanotti, PhD
Pluripotent mesenchymal cells in the bone marrow can
differentiate into osteoblasts, adipocytes, and chondrocytes.
Runx233 and Osterix34 are transcription factors required for oste-
oblast differentiation, and their expression characterizes cells
committed to the osteoblastic lineage.35 Differentiation of mes-
enchymal cells to the osteoblastic lineage is regulated by a net-
work of signaling pathways that includes bone morphogenetic
protein/signaling mothers against decapentaplegic (BMP/Smad),
and Wnt.36 There is growing evidence that inflammation sup-
presses osteoblast activity and bone formation. However, the
mechanisms for this effect are less clear. TNF-a suppresses
osteoblastogenesis, possibly by inhibiting the activity of BMP/
Smad37 and Wnt.38 The Notch pathway may also be affected by
inflammatory signals emerging from the diseased intestine,39
which may offer an additional explanation for the decreased
bone mass observed in pathologies with a prominent inflamma-
tory element, such as CD.
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Future Directions
Future directions are to investigate the effects of inflam-
mation on the signaling pathways that determine osteoblasto-
genesis to clarify the connection between inflammatory diseases
and the lack of bone formation.
OSTEOCLASTS, INFLAMMATION, AND IBD
Francisco Sylvester, MD
RANKL produced by osteoblasts and bone marrow stromal
cells is an essential cytokine for osteoclast development. RANKL
binds to its receptor RANK on osteoclast precursors and induces
osteoclast differentiation and activation.40 In addition, costimula-
tion through immunoglobulin-like receptors and their ligands is
required to form osteoclasts.41 Activated T cells, particularly Th17
cells that have an important role in the pathogenesis of IBD, can
produce RANKL.42 Cytokines such as TNF-a, IL-6, IL-17, and
IFN-g that are found in the inflamed intestinal mucosa in IBD
may regulate osteoclast development by regulating the RANKL
signaling pathway.43,44 These cytokines may act on osteocytes
that are an important source of RANKL in bone.45,46 Moreover,
in IBD, osteoclasts may directly respond to environmental signals
in the bone microenvironment, including cytokines, chemokines,
prostaglandins, and pathogen-associated molecular patterns and
become more or less developed and activated in different regions
of the bone.
In children with IBD, osteoclast activity seems to be
suppressed, at least at diagnosis. However, regional differences
in osteoclast function responsible for expanding the bone marrow
cavity and lengthening the bones may make long bones thinner
and weaker in children with IBD.3 The behavior of osteoclasts
may also change with therapies such as corticosteroids and bio-
logics and with disease progression.
Future Directions
Future directions are to better understand the systemic and
local signals that control osteoclast differentiation and function in
pediatric IBD.
IMPACT OF IBD ON GROWTH AND
BONE HEALTH
The previous discussion underscored several mechanisms
by which intestinal inflammation may reduce bone formation and
linear growth and augment bone resorption. The purpose of the
following section is to understand how IBD impacts linear growth
and the skeleton in the clinic and to identify opportunities to
improve final adult height and peak bone mass in young patients
with IBD.
To understand the effects of IBD on bone, one should
consider that bone and skeletal muscle form a functional unit.47
Physical activity influences bone metabolism both directly and
indirectly. If dynamic strain during exercise exceeds an upper
threshold, the bone-forming cells, osteoblasts, are stimulated
and form the bone matrix. Weight-bearing activities like gymnas-
tics, running, or jumping activities induce high dynamic loads and
therefore enhance bone growth and formation and may be a ther-
apeutic option to enhance bone mass in children with IBD.
THE ROLE OF BONE HISTOMORPHOMETRY IN
PEDIATRIC IBD BONE AND GROWTH RESEARCH
Frank Rauch, MD
Dr. Rauch and colleagues evaluated static histomorphometry
on transiliac bone samples in 20 patients (age range 8.4–17.7 yr,
12 males/8 females) with newly diagnosed CD and compared the
results with reference data from their laboratory.2,48 This study
revealed a slightly low cortical width but a normal amount of
trabecular bone.2 However, the percentage of trabecular bone sur-
face covered by osteoid or osteoclasts was low, suggesting that both
bone formation and bone resorption were suppressed. Therefore,
histomorphometry of transiliac bone biopsies suggests that young
patients with CD have slow trabecular bone turnover at diagnosis.
Future Directions
Transiliac bone biopsy can be easily performed by trained
physicians. Bone histomorphometry should be part of the
evaluation of children with low bone mass to better understand
how IBD affects bone architecture and bone cell function and
direct treatment for low bone mass appropriately.
STRUCTURAL BASES OF BONE FRAGILITY IN
YOUNG PATIENTS WITH IBDS
Serge Ferrari, MD*
Dr. Ferrari and colleagues recruited patients with CD (n¼ 76),
ulcerative colitis (n ¼ 29), and IBD undefined (n ¼ 3) from the
Swiss IBD cohort. Dual x-ray absorptiometry (DXA) (Discovery
A; Hologic, Bedford, MA) measured areal bone mineral density
(BMD) at the distal radius, hip, and spine. The DXA scanner also
performed vertebral fracture analysis. High-resolution peripheral
quantitated computed tomography (pQCT) (XtremeCT; Scanco,
Brüttisellen, Switzerland) determined volumetric bone mineral
density and trabecular and cortical bone microstructure at distal
radius and tibia. Questionnaires recorded clinical fractures, dis-
ease characteristics, and environmental variables. BMD and
microstructure were compared between subjects with IBD and
345 age, sex, height, and fracture history matched healthy con-
trols. Dr. Ferrari compared patients who did and did not sustain
fractures and adjusted for multiple confounders.
The mean age of IBD subjects was 22.8 years and mean
duration of IBD was 6.1 years (range 1.0–22.3 years). Clinical
fractures were reported by 39 patients with IBD (36%; mean age
of 12.6 yr at first fracture). The majority of fractures were at the
forearm, arm, or hand. Five subjects had morphometric vertebral
fractures (grade 1 or 2) and 11 had multiple fractures. Dr. Ferrari
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observed that young subjects with IBD have low bone mineral
density and poor bone microarchitecture compared with healthy
controls.
Future Directions
Future studies should examine what therapies for IBD are
associated with the highest risk of alterations in bone micro-
architecture, particularly in the trabecular bone compartment, which
are specifically associated with fractures in patients with IBD.
THE FUNCTIONAL MUSCLE–BONE UNIT
IN PEDIATRIC IBD
Leanne Ward, MD*
Children with CD often have a reduction in lean mass
(sarcopenia), potentially owing to nutritional compromise and
inflammatory mediation by cytokines. Previous studies have
suggested that sarcopenia may be responsible for the low bone
mass in children with CD. Therefore, Dr. Ward and colleagues
examined the “muscle–bone phenotype” in pediatric CD and
determined whether sarcopenia of leg muscles is associated with
a reduction in leg muscle function and bone deficits. Between
2008 and 2011, she enrolled 67 children (mean age of 13.5 yr,
mean bone age 13.8 yr; 62% males) with confirmed diagnosis of
CD. Over 90% of the subjects had moderate/severe CD. Dr. Ward
used DXA of the spine, metacarpal morphometry for cortical and
marrow area evaluation, and pQCT of the tibia to examine tra-
becular and cortical density, bone mineral content, and tibia mus-
cle cross-sectional area. A dynamic measure of strength, “jumping
mechanography” used the Leonardo Force Plate (Novotec Medi-
cal GmbH, Pforzheim, Germany), to measure peak jump power
per body weight on a single 2-legged jump.
Dr. Ward found that leg muscle mass at the tibia was
significantly reduced in children with newly diagnosed CD
compared with controls, along with a significant reduction in peak
jump power. Although both muscle mass and bone mass were
reduced, the amount of bone was appropriate for the amount of
muscle mass. Dr. Ward also observed a high cortical density of long
bones, probably secondary to low intracortical remodeling activity.
Future Directions
Sarcopenia in children with CD is associated with
decreased muscle power and strength and reduced bone mass.
Future studies should assess the impact of exercise programs on
muscle mass, strength, and power in children with IBD.
Sibylle Koletzko, MD
Dr. Koletzko and colleagues performed a longitudinal study
in a large cohort of children with IBD where she measured BMD
and muscle mass with pQCT of the lower arm on a yearly basis,
some starting at the time of diagnosis and others later in the
disease course. Newly diagnosed patients had the lowest z scores
for muscle mass. Muscle mass z score improved over time, but it
did not normalize over the duration of the study in children with
IBD.49–51 Dr. Koletzko hypothesized that bone adapts to the
smaller muscle mass in pediatric IBD, resulting in a low bone
mass, bone strength, and different bone geometry as compared
with healthy children.
Dr. Koletzko also examined the grip force, number of daily
steps, and energy expenditure over 3 days in 39 children with IBD
compared with age-based and sex-based controls. Grip force and
number of steps were lower in the patient group. Patients with IBD
tended to have more sedated daily activity and more sleep time.51
Dr. Koletzko presented another study of trabecular and
cortical BMD in children with CD treated with exclusive enteral
nutrition over 8 weeks followed by stepwise introduction of
a regular diet. The muscle mass of the patients with CD improved
dramatically with exclusive enteral nutrition. Cortical BMD
decreased and trabecular BMD increased, suggesting activation
of bone turnover with enteral nutrition. However, the gains
incurred during exclusive enteral feeding therapy were not
sustained after a normal diet was resumed.50,51
Future Directions
Future studies should evaluate whether bone strength in
children with IBD can be improved by physical activity programs
that increase muscle mass, especially during puberty when most
bone mass normally accumulates.
SEX DIFFERENCES IN STATURAL GROWTH
IMPAIRMENT IN PEDIATRIC PATIENTS WITH CD
Neera Gupta, MD, MAS
Dr. Gupta and colleagues studied 989 pediatric patients
with CD enrolled in the Pediatric IBD Consortium Registry. She
found that although the overall course of disease was more severe
in females,52,53 the cumulative incidence of growth failure was
greater in males.53 These data suggest that the negative impact
of disease severity on linear growth differs by sex.
Dr. Gupta also reported on a cross-sectional study of linear
growth in 82 patients with CD (43% female) younger than 21 years
of age followed between 2007 and 2009.54 She observed that serum
insulin-like growth factor 1 (IGF-1) adjusted to chronological age
and bone age z scores were lower in males than females. Lower
IGF-1 in males may explain sex differences in growth impairment
in CD. Inflammation appears to more adversely affect hormone
levels and linear growth in males.
Future Directions
Prospective longitudinal studies are needed to clarify the
etiology of sex differences in growth impairment in pediatric CD.
APPROACHES TO ADDRESS GROWTH FAILURE
AND LOW BONE MASS IN CHILDREN WITH IBD
Pediatric IBD is associated with low bone remodeling and
modeling and sarcopenia due to disease and treatment factors. The
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inflammation caused by IBD in children may have long-term effects
on bone health, adult height, muscle strength, and maturation if not
recognized and treated. In this session, inflammation, malnutrition
(with associated reductions in IGF-1), and vitamin D deficiency
were explored as therapeutic targets for intervention for children
with CD and ulcerative colitis.
CHANGES IN BONE AND MUSCLE AND MUSCLE
MASS AFTER TNF-ALPHA INHIBITION IN
PEDIATRIC CD
Meena Thayu, MD, MSCE
Dr. Thayu and colleagues described changes in bone
turnover markers during infliximab induction therapy in pediatric
CD and identified determinants of 12-month improvements in
bone and muscle mass after initiation of this therapy. The study
prospectively enrolled 74 subjects (63% male, 5–21 yr of age)
initiating infliximab for the first time. The pQCT measurements
were converted to race-specific z scores. Trabecular and cortical
BMD were determined relative to age. Cortical dimensions and
muscle area relative to tibia length were adjusted for age. Bone
biomarkers were converted to Tanner stage–specific z scores.
Infliximab therapy was associated with marked increase in
the bone formation marker bone-specific alkaline phosphatase at
10 weeks and with improvements in height z score at 54 weeks.55
Trabecular BMD increased, cortical BMD decreased, and endocort-
ical bone recovered, changes consistent with new bone formation.
Greater height velocity was associated with greater changes in
volumetric BMD, endosteal, and muscle cross-sectional area z
scores. Deficits in periosteal and section modulus persisted, despite
other improvements.56
The results indicate that recovery of linear growth, bone
density, bone dimensions and strength, and muscle mass in
patients with CD treated with infliximab is most likely to occur in
younger that have growth potential.
Future Directions
The next set of analyses will incorporate measures of
physical activity, dietary intake, osteoprotegerin/receptor activator
of nuclear factor kΒ, cytokine and growth factor levels, vitamin D,
and PTH levels.
PHARMACOKINETIC STUDIES OF RECOMBINANT
HUMAN IGF-1 IN CHILDREN WITH CD-INDUCED
GROWTH RETARDATION
Ian Sanderson, MD*
The best treatment for growth failure in CD is treatment
of inflammation; however, there are cases where the use of
recombinant human IGF-1 may be useful to treat poor growth.
This study is aimed at developing a pharmacokinetic model for
safe and effective dosing of recombinant IGF-1 in children
with CD.
In a rat model of colitis, Dr. Ian Sanderson and colleagues
established that inflammation by itself can suppress linear growth,
independent of malnutrition.57 IGF-1 is depressed in rats with
colitis, and injections of IGF-1 help to restore linear growth. This
finding stimulated Dr. Sanderson to consider the use of IGF-1 in
children with CD with active inflammation, despite therapy and
poor growth. A first step was to study the pharmacokinetics of
IGF-1 in children with CD. Dr. Sanderson and colleagues de-
signed a study of 8 children with CD to determine the optimal
dosing model for IGF-1. Each child was hospitalized twice with
informed consent. Each child had a first dose of IGF-1, and levels
were followed over 24 hours. Three months later, each child was
admitted for 5 days, and 12-hour dosing took place on alternate
days. Although some children with active CD had protein-losing
enteropathy, intestinal losses did not affect the rate of IGF-1
decline after dosing. This dosing model takes into account patient
weight and disease activity and is able to restore normal circulat-
ing levels of IGF-1 in children with CD receiving recombinant
IGF-1 therapeutically.
Future directions
A long-term study to evaluate the safety and efficacy of
IGF-1 for growth enhancement in children with growth delay who
are resistant to anti-inflammatory medications.
OPTIMIZATION OF VITAMIN D STATUS AND ITS
IMPACT ON BONE AND HEALTH AND DISEASE
OUTCOMES IN YOUNG PATIENTS WITH IBD
Helen Pappa, MD, MPH
Dr. Pappa reported on a study comparing patients with IBD
to healthy adolescents, where 34.6% of patients with IBD had
25OHD ,15 ng/mL versus 24% in healthy adolescents, at the
same center.58 Risk factors for low 25OHD in children with IBD
included winter season, dark skin, low BMI z score, low serum
albumin, high ESR, corticosteroid exposure, and upper gastroin-
testinal disease.
Dr. Pappa and colleagues went on to examine the efficacy
and safety of 3 regimens to treat hypovitaminosis D (25OHD
level# 20 ng/mL) in patients 5 to 21 years with IBD: 2000 IU D2
per day; 2000 IU D3 per day, and 50,000 IU D2 per week all
administered orally for 6 weeks, each in 20 subjects allocated
randomly. All patients also received 800 or 1200 mg of calcium
per day. There were no serious adverse events. The highest dose
of vitamin D (50,000 IU/wk) was the most effective to raise serum
25OHD and should therefore be the regimen of choice to treat
hypovitaminosis D in children with IBD.58 Interestingly, serum
PTH response was blunted in children with IBD for unknown
mechanisms that may have to do with relative insensitivity of
the calcium sensing receptor in the parathyroid gland in IBD.
Dr. Pappa and colleagues also evaluated 2 maintenance
regimens, each including 30 patients assigned randomly: 400 IU
D2 per day for 1 year or 2000 IU D2 per day from November to
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April and 1000 IU per day from May to December. Neither
regimen maintained the serum 25OHD .32 ng/mL throughout
the year and were only 65% to 68% effective to keep 25OHD
.20 ng/mL throughout the year. The higher dose regimen was
associated with a slightly higher mean 25OHD level. Serum IL-6
was lower in subjects receiving the higher dose of vitamin D.58
None of the regimens was associated with improved BMD scores.
Future Directions
To determine a target serum 25OHD level that results in
optimal bone health and improved disease outcomes and vitamin D
supplementation regimens that enable the target level. The mech-
anisms behind the blunted PTH response to low vitamin D need to
be examined. The role of vitamin D analog or other vitamin D
receptor agonists in management of inflammation could also be an
opportunity for investigation.
SUMMARY AND CONCLUSIONS
Pediatric IBD, especially CD, is associated with significant
and persistent alterations in bone mass and architecture and in
skeletal muscle mass and strength. Suppression of osteoblast (and
perhaps osteocyte) function and regional upregulation of osteoclast
function by inflammatory factors play significant roles. It is
possible that intestinal inflammation affects the regenerative
capacity of muscle stem cells. Therefore, the functional bone–
muscle unit is impaired in pediatric IBD. Routinely obtaining accu-
rate height and weight, Tanner stage, and menstrual history is essen-
tial to identify children whose growth and pubertal progression are
delayed. Current technologies including DXA, pQCT, and bone
histomorphometry of transiliac bone biopsy can accurately charac-
terize the impact of IBD on bone and muscle in individual patients.
Certain treatments such as TNF-a blockers and enteral nutritional
therapy offer promise to increase bone formation and linear growth.
These observations need to be confirmed, and additional therapies
need to be identified that achieve the same anabolic effects on bone,
muscle, and growth in pediatric IBD. Adequate dietary intake of
calcium and maintenance of serum 25OHD .20 ng/mL should
ensure sufficient substrate to mineralize bone adequately. This goal
may be difficult to achieve in some children with IBD. Patients
whose growth failure persists despite adequate disease control or
in whom disease control is difficult to achieve with current therapies
may be candidates for treatment with growth hormone or IGF-1 if
there is growth hormone resistance. When designing therapies to
improve bone mass and linear growth, important differences
between males and females should be taken into account. Despite
excellent progress obtained as a consequence of this CCFA funding
mechanism, many key questions remain. Children afflicted by IBD
and their families eagerly await the results of new research.
REFERENCES
1. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metab-
olism and bone mineral density in children with inflammatory bowel
disease. Inflamm Bowel Dis. 2007;13:42–50.
2. Ward LM, Rauch F, Matzinger MA, et al. Iliac bone histomorphometry in
children with newly diagnosed inflammatory bowel disease. Osteoporos
Int. 2010;21:331–337.
3. Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of
bone density and structure in an incident cohort of children with Crohn’s
disease. Gastroenterology. 2009;136:123–130.
4. Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of
children with Crohn’s disease. Gut. 1993;34:939–943.
5. Markowitz J, Grancher K, Rosa J, et al. Growth failure in pediatric inflam-
matory bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373–380.
6. Harris L, Senagore P, Young VB, et al. Inflammatory bowel disease
causes reversible suppression of osteoblast and chondrocyte function in
mice. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1020–G1029.
7. McCabe LR, Irwin R, Schaefer L, et al. Probiotic use decreases intestinal
inflammation and increases bone density in healthy male but not female
mice. J Cell Physiol. 2013;228:1793–1798.
8. Nylund CM, D’mello S, Kim MO, et al. Granulocyte macrophage-colony-
stimulating factor autoantibodies and increased intestinal permeability in
Crohn disease. J Pediatr Gastroenterol Nutr. 2011;52:542–548.
9. D’Mello S, Trauernicht A, Ryan A, et al. Innate dysfunction promotes
linear growth failure in pediatric Crohn’s disease and growth hormone
resistance in murine ileitis. Inflamm Bowel Dis. 2012;18:236–245.
10. Roth L, MacDonald JK, McDonald JW, et al. Sargramostim (GM-CSF)
for induction of remission in Crohn’s disease: a cochrane inflammatory
bowel disease and functional bowel disorders systematic review of ran-
domized trials. Inflamm Bowel Dis. 2012;18:1333–1339.
11. Lee JJ, Escher JC, Shuman MJ, et al. Final adult height of children with
inflammatory bowel disease is predicted by parental height and
patient minimum height Z-score. Inflamm Bowel Dis. 2010;16:1669–1677.
12. Hewison M. Vitamin D and the immune system: new perspectives on an
old theme. Rheum Dis Clin North Am. 2012;38:125–139.
13. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by
1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-
dependent pathway that promotes a persistent state of immaturity in vitro
and in vivo. Proc Natl Acad Sci U S A. 2001;98:6800–6805.
14. Hewison M, Freeman L, Hughes SV, et al. Differential regulation of
vitamin D receptor and its ligand in human monocyte-derived dendritic
cells. J Immunol. 2003;170:5382–5390.
15. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicro-
bial peptide (CAMP) gene is a direct target of the vitamin D receptor and
is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3.
FASEB J. 2005;19:1067–1077.
16. Yu S, Cantorna MT. The vitamin D receptor is required for iNKT cell
development. Proc Natl Acad Sci U S A. 2008;105:5207–5212.
17. Wu S, Liao AP, Xia Y, et al. Vitamin D receptor negatively regulates
bacterial-stimulated NF-{kappa}B activity in intestine. Am J Pathol.
2010;177:686–697.
18. von Essen MR, Kongsbak M, Schjerling P, et al. Vitamin D controls T
cell antigen receptor signaling and activation of human T cells. Nat
Immunol. 2010;11:344–349.
19. Simmons JD, Mullighan C, Welsh KI, et al. Vitamin D receptor gene
polymorphism: association with Crohn’s disease susceptibility. Gut
2000;47:211–214.
20. IOM (Institute of Medicine). Dietary reference intakes for calcium and
vitamin D. Washington, DC: The National Academies Press; 2011.
21. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treat-
ment, and prevention of vitamin D deficiency: an Endocrine Society Clin-
ical Practice Guideline. J Clin Endocrinol Metab. 2011;96:1911–1930.
22. Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and
adolescents with inflammatory bowel disease. J Pediatr Gastroenterol
Nutr. 2011;53:11–25.
23. Ryz NR, Patterson SJ, Zhang Y, et al. Active vitamin D (1,25-
dihydroxyvitamin D3) increases host susceptibility to Citrobacter
rodentium by suppressing mucosal Th17 responses. Am J Physiol
Gastrointest Liver Physiol. 2012;303:G1299–G1311.
24. Wang TT, Dabbas B, Laperriere D, et al. Direct and indirect induction by 1,25-
dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune
pathway defective in Crohn disease. J Biol Chem. 2010;285:2227–2231.
25. Liu N, Nguyen L, Chun RF, et al. Altered endocrine and autocrine metab-
olism of vitamin D in a mouse model of gastrointestinal inflammation.
Endocrinology. 2008;149:4799–4808.
Inflamm Bowel Dis  Volume 19, Number 13, December 2013 Report of the CCFA Workshop
www.ibdjournal.org | 2925
Copyright © 2013 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
26. Lagishetty V, Misharin AV, Liu NQ, et al. Vitamin D deficiency in mice
impairs colonic antibacterial activity and predisposes to colitis. Endocri-
nology. 2010;151:2423–2432.
27. Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vita-
min D levels in inflammatory bowel disease patients reveals a subset of
Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low
bone mineral density. Gut. 2004;53:1129–1136.
28. Wright TB, Shults J, Leonard MB, et al. Hypovitaminosis D is associated
with greater body mass index and disease activity in pediatric systemic
lupus erythematosus. J Pediatr. 2009;155:260–265.
29. Amital H, Szekanecz Z, Szucs G, et al. Serum concentrations of 25-OH
vitamin D in patients with systemic lupus erythematosus (SLE) are
inversely related to disease activity: is it time to routinely supplement
patients with SLE with vitamin D? Ann Rheum Dis. 2010;69:1155–1157.
30. von Scheven E, Burnham JM. Vitamin D supplementation in the pediatric
rheumatology clinic. Curr Rheumatol Rep. 2011;13:110–116.
31. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway
identifies a subgroup of systemic lupus erythematosus patients with distinct
serologic features and active disease. Arthritis Rheum. 2005;52:1491–1503.
32. Takayanagi H. New developments in osteoimmunology. Nat Rev Rheu-
matol. 2012;8:684–689.
33. Takarada T, Hinoi E, Nakazato R, et al. An analysis of skeletal develop-
ment in osteoblast- and chondrocyte-specific Runx2 knockout mice.
J Bone Miner Res. 2013;28:2064–2069.
34. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing
transcription factor osterix is required for osteoblast differentiation and
bone formation. Cell. 2002;108:17–29.
35. Canalis E, Parker K, Feng JQ, et al. Osteoblast lineage-specific effects of
notch activation in the skeleton. Endocrinology. 2013;154:623–634.
36. Canalis E. Growth factor control of bone mass. J Cell Biochem. 2009;108:
769–777.
37. Guo R, Yamashita M, Zhang Q, et al. Ubiquitin ligase Smurf1 mediates
tumor necrosis factor-induced systemic bone loss by promoting proteaso-
mal degradation of bone morphogenetic signaling proteins. J Biol Chem.
2008;283:23084–23092.
38. Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects
from systemic bone loss during inflammation and reduces sclerostin
expression. Ann Rheum Dis. 2010;69:2152–2159.
39. Zanotti S, Canalis E. Notch regulation of bone development and remod-
eling and related skeletal disorders. Calcif Tissue Int. 2012;90:69–75.
40. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteo-
clastogenesis, lymphocyte development and lymph-node organogenesis.
Nature. 1999;397:315–323.
41. Mori Y, Tsuji S, Inui M, et al. Inhibitory immunoglobulin-like receptors
LILRB and PIR-B negatively regulate osteoclast development. J Immunol.
2008;181:4742–4751.
42. Kikuta J, Wada Y, Kowada T, et al. Dynamic visualization of RANKL
and Th17-mediated osteoclast function. J Clin Invest. 2013;123:866–873.
43. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and
joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Nature. 1999;402:304–309.
44. Onal M, Xiong J, Chen X, et al. Receptor activator of nuclear factor kappaB
ligand (RANKL) protein expression by B lymphocytes contributes to ovari-
ectomy-induced bone loss. J Biol Chem. 2012;287:29851–29860.
45. Nakashima T, Hayashi M, Fukunaga T, et al. Evidence for osteocyte
regulation of bone homeostasis through RANKL expression. Nat Med.
2011;17:1231–1234.
46. Xiong J, Onal M, Jilka RL, et al. Matrix-embedded cells control osteoclast
formation. Nat Med. 2011;17:1235–1241.
47. Schonau E, Werhahn E, Schiedermaier U, et al. Influence of muscle
strength on bone strength during childhood and adolescence. Horm Res.
1996;45(suppl 1):63–66.
48. Glorieux FH, Travers R, Taylor A, et al. Normative data for iliac bone
histomorphometry in growing children. Bone. 2000;26:103–109.
49. Bechtold S, Alberer M, Arenz T, et al. Reduced muscle mass and bone
size in pediatric patients with inflammatory bowel disease. Inflamm Bowel
Dis. 2009;16:2016–2227.
50. Werkstetter KJ, Pozza SB, Filipiak-Pittroff B, et al. Long-term develop-
ment of bone geometry and muscle in pediatric inflammatory bowel dis-
ease. Am J Gastroenterol. 2011;106:988–998.
51. Werkstetter KJ, Ullrich J, Schatz SB, et al. Lean body mass, physical
activity and quality of life in paediatric patients with inflammatory bowel
disease and in healthy controls. J Crohns Colitis. 2012;6:665–673.
52. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in
pediatric patients with Crohn’s disease. Gastroenterology. 2006;130:
1069–1077.
53. Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in pre-
sentation and course of disease in pediatric patients with Crohn disease.
Pediatrics. 2007;120:e1418–e1425.
54. Gupta N, Lustig RH, Kohn MA, et al. Sex differences in statural growth
impairment in Crohn’s disease: role of IGF-1. Inflamm Bowel Dis. 2011;
17:2318–2325.
55. Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone
formation during infliximab therapy in pediatric Crohn’s disease: results of
the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378–1384.
56. Thayu M, Denson LA, Shults J, et al. Determinants of Changes in linear
growth and body composition in incident pediatric Crohn’s disease. Gas-
troenterology. 2010;139:430–438.
57. Sawczenko A, Azooz O, Paraszczuk J, et al. Intestinal inflammation-
induced growth retardation acts through IL-6 in rats and depends on the
-174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A.
2005;102:13260–13265.
58. Pappa HM, Mitchell PD, Jiang H, et al. Treatment of vitamin D insuffi-
ciency in children and adolescents with inflammatory bowel disease:
a randomized clinical trial comparing three regimens. J Clin Endocrinol
Metab. 2012;97:2134–2142.
Sylvester et al Inflamm Bowel Dis  Volume 19, Number 13, December 2013
2926 | www.ibdjournal.org
Copyright © 2013 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
